A phase I study of PT-112 in advanced solid tumors.

被引：3
|
作者：
Karp, Daniel D.
Camidge, D. Ross
Bryce, Alan Haruo
Jimeno, Jose
Infante, Jeffrey R.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase I Program, Houston, TX 77030 USA
[2] Univ Colorado Denver, Aurora, CO USA
[3] Mayo Clin, Phoenix, AZ USA
[4] Pangaea Biotech SL, Barcelona, Spain
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Tennessee Oncol PLLC, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2519
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2519
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors.
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] A phase I study evaluating COM701 in patients with advanced solid tumors.
    Rasco, Drew W.
    Papadopoulos, Kyriakos P.
    Adewoye, Adeboye H.
    Hunter, John
    Ramsey, Denise
    ElNaggar, Adam
    Patnaik, Amita
    Vaena, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [23] A phase I and pharmacokinetic study of PEG-camptothecin in patients with advanced solid tumors.
    Hao, D
    Tolcher, AW
    Rizzo, JD
    Ochoa, L
    McCreery, H
    Schwartz, GH
    Patnaik, A
    Denis, LJ
    Hammond, LA
    Hidalgo, M
    Kwiatek, J
    McGuire, J
    Rowinsky, EK
    CLINICAL CANCER RESEARCH, 2000, 6 : 4513S - 4513S
  • [24] Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.
    van der Noll, Ruud
    Ang, Joo Ern
    Jager, Agnes
    Marchetti, Serena
    Mergui-Roelvink, Marja
    De Bono, Johann Sebastian
    Lolkema, Martijn
    Brunetto, Andre
    Arkenau, Hendrik-Tobias
    De Jonge, Maja J.
    van der Biessen, Diane
    Tchakov, Ilian
    Bowen, Karin
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A phase I study evaluating COM701 in patients with advanced solid tumors.
    Rasco, Drew W.
    Vaena, Daniel A.
    Sullivan, Ryan J.
    Luke, Jason J.
    ElNaggar, Adam
    Hunter, John
    Adewoye, Adeboye H.
    Olweny, Judy
    Patnaik, Amita
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors.
    Dudek, A
    Larson, T
    Mellskog, CE
    Bloss, LP
    Obasaju, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 162S - 162S
  • [27] Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors.
    Chiappori, A
    Simon, GR
    Kvols, L
    Tetteh, L
    Mahany, JJ
    Lush, R
    Sullivan, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 160S - 160S
  • [28] Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors.
    Gold, PJ
    Refice, S
    West, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 164S - 164S
  • [29] Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.
    Westin, Shannon Neville
    Smart, Melody L.
    Pal, Navdeep
    Urbauer, Diana L.
    Janku, Filip
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Naing, Aung
    Tsimberidou, Apostolia Maria
    Fu, Siqing
    Falchook, Gerald Steven
    Hong, David S.
    Zinner, Ralph
    Subbiah, Vivek
    Culotta, Kirk Salvatore
    Lu, Karen H.
    Coleman, Robert L.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] A phase I Study of MEDI 522 inpatients with advanced tumors.
    McNeel, DG
    Thomas, JP
    Lee, FT
    Friedl, A
    Marnocha, R
    Tutsch, K
    Volkman, J
    Binger, K
    Lakner, M
    Alberti, DB
    Eickhoff, J
    Wilding, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6190S - 6190S
12345